Blood pressure (BP) control. Hypertension
|
|
- Conrad Washington
- 5 years ago
- Views:
Transcription
1
2 Blood pressure (BP) control
3 Normal heart function
4 Blood pressure (BP) control blood pressure (BP) cardiac output (CO) = total peripheral resistance (TPR) heart rate (HR) filling pressure arteriolar volume contractility blood volume venous tone
5 Blood pressure (BP) control 1. Baroreceptors aortic arch and carotid sinus kidneys 2. Autonomic control sympathetic (adrenergic) para-sympathetic (cholinergic) 3. Renin-angiotensin-aldosterone system (RAAS) 4. Chemoreceptors 5. CNS control 6. Vasopressin (anti-diuretic hormone)
6 Blood pressure (BP) control 1. Baroreceptors aortic arch and carotid sinus kidneys 2. Autonomic control sympathetic (adrenergic) para-sympathetic (cholinergic) 3. Renin-angiotensin-aldosterone system (RAAS) 4. Chemoreceptors 5. CNS control 6. Vasopressin (Anti-diuretic hormone)
7 Sympathetic control rapid, momentary regulation affects sympathetic and para-sympathetic systems alters vascular constriction and CO
8 Sympathetic control
9 Sympathetic control
10 RAAS control long-term regulation affects angiotensin-ii and aldosterone secretion potent vasoconstrictor affects vascular constriction controls water balance affects blood volume
11 RAAS control
12 Combined control sympathetic activity BLOOD PRESSURE DECREASED renal blood flow cardiac β 1 -adrenoceptors activated smooth muscle α 1 -adrenoceptors activated Sympathetic mediation renin RAAS mediation angiotensin-ii CO TPR BLOOD PRESSURE INCREASED aldosterone Glomerular filtration rate Na +, water retention blood volume
13 (HTN) Classical definition BP > 140/90 NHLBI previous classification Category Normal High Normal Stage 1 (mild HTN) Stage 2 (moderate HTN) Stage 3 (severe HTN) Stage 4 (very severe HTN) Systolic (mm Hg) < Diastolic (mm Hg) <
14 (HTN) Risk assessment Other Risk Factors & Disease History Grade 1 (mild hypertension) SBP or DBP BLOOD PRESSURE (mmhg) Grade 2 (moderate hypertension) SBP or DBP Grade 3 (severe hypertension) SBP 180 or DBP 110 I. no other risk factors LOW RISK MED RISK HIGH RISK II. 1-2 risk factors MED RISK MED RISK VERY HIGH RISK III. 3 or more risk factors or TOD 1 or diabetes HIGH RISK HIGH RISK VERY HIGH RISK IV. ACC 2 VERY HIGH RISK VERY HIGH RISK VERY HIGH RISK 1 - TOD = Target Organ Damage 2 - ACC = Associated Clinical Conditions, including clinical cardiovascular disease and renal disease.
15 JNC-7 guidelines 2003 HTN prevalence - USA: ~ 50 million people
16 JNC-7 guidelines 2003
17 JNC-7 guidelines 2003 Benefits of Lowering BP average % reduction stroke incidence 35 40% myocardial infarction 20 25% heart failure 50% In stage 1 HTN and additional CVD risk factors, achieving a sustained 12 mmhg reduction in SBP over 10 years will prevent 1 death for every 11 patients treated (NNT=11).
18 JNC-7 guidelines 2003 Benefits of Lowering BP the BP relationship to risk of CVD is continuous, consistent, and independent of other risk factors. each increment of 20/10 mmhg doubles the risk of CVD across the entire BP range starting from 115/75 mmhg.
19 JNC-7 guidelines 2003 Benefits of Lowering BP for persons over age 50, SBP is a more important than DBP as CVD risk factor. those with SBP mmhg or DBP mmhg should be considered pre-hypertensive who require health-promoting lifestyle modifications to prevent CVD.
20 JNC-7 guidelines 2003 Goals of antihypertensive therapy reduce CVD and renal morbidity and mortality. treat to BP <140/90 mmhg or BP <130/80 mmhg in patients with diabetes or chronic kidney disease. achieve SBP goal especially in persons >50yo.
21 JNC-7 guidelines 2003
22 JNC-7 guidelines 2003 Identifiable causes of HTN sleep apnea drug-induced or related causes chronic kidney disease primary aldosteronism reno-vascular disease chronic steroid therapy and Cushing s syndrome pheochromocytoma coarctation of the aorta thyroid or parathyroid disease
23 JNC-7 guidelines 2003
24 JNC-7 guidelines 2003 HTN-related target organ damage heart left ventricular hypertrophy angina or prior myocardial infarction prior coronary revascularization heart failure brain stroke or transient ischemic attack chronic kidney disease peripheral arterial disease retinopathy
25 JNC-7 guidelines 2003 Lifestyle modifications Modification weight reduction DASH eating plan dietary Na + reduction physical activity alcohol consumption Approximate SBP reduction 5-20 mmhg/10 kg weight loss 8-14 mmhg 2-8 mmhg 4-9 mmhg 2-4 mmhg
26 Therapeutic options: Diuretics β-blockers α 1 -blockers Calcium-channel blockers RAAS modifiers Other
27 Therapeutic options: Diuretics β-blockers α 1 -blockers Calcium-channel blockers RAAS modifiers Other
28 Diuretics (thiazides) currently considered 1 st line (elderly) effective in low oral doses (monotherapy/combination) reduce mortality (stroke, MI, CHF) Hydrochlorothiazide (HCTZ) = Disothiazide
29 Thiazide diuretics most effective diuretics in HTN mechanism: peripheral resistance Na +, H 2 O excretion blood volume blood pressure cardiac output
30 Thiazide diuretics - PK good bioavailability (50-80%) not metabolized HCTZ T 1/2-6-12hr renal excretion HCTZ dosing range mg/d ineffective in moderate-severe renal failure (metolazone/indapamide)
31 Thiazide diuretics - PD HCTZ (mg/d)
32 Thiazide diuretics - ADEs hypokalemia (common) - monitor per risk factors hyperuricemia (common) hyperglycemia (10%) hypomagnesemia
33 Thiazide diuretics - DDIs digoxin (hypokalemia may exacerbate digoxin effect) lithium (thazides reduce lithium renal clearance) other diuretic/hypotensive medications (additive effect)
34 Potassium-sparing diuretics spironolactone (Aldospirone ) reduce K + excretion mild hypotensive effect
35 Loop diuretics furosemide (Fusid ) not used as hypotensives: less effective short T 1/2
36 Therapeutic options: Diuretics β-blockers α 1 -blockers Calcium-channel blockers RAAS modifiers Other
37 β-blockers (BBs)- mechanism β-blocker administration 1 2 cardiac β 1 receptor activation renin release cardiac output angiotensin-ii formation peripheral resistance blood pressure aldosterone secretion Na+, H2O excretion blood volume
38 β-blockers selectivity β 1 vs. β 2 non-selective: propranolol = Deralin, Prolol β 1 -selective: atenolol = Normiten, Normalol metoprolol = Lopressor, Neobloc bisoprolol = Concor, Cardiloc
39 β-blockers - ADEs bradycardia hypotension fatigue insomnia sexual dysfunction altered lipid profile
40 β-blockers - DDIs effect of hypoglycemics effect of digoxin, CCBs, α-blockers, other hypotensives β-blockers precautions and contra-indications might mask hypoglycemic effect of hypoglycemics β 2 -blockade in respiratory disease (propranolol - C/I) severe CHF
41 β-blockers - therapeutic considerations more effective in caucasians than in blacks (as monotherapy) additional benefit in concomitant diseases (CHF, IHD, migraine, post-mi, certain arrhythmias)
42 Therapeutic options: Diuretics β-blockers α 1 -blockers Calcium-channel blockers RAAS modifiers Other
43 α 1 -blockers - mechanism α 1 -blocker administration smooth muscle relaxation arterial venous peripheral resistance blood pressure
44 α-blockers - therapeutic considerations α 1 vs. α 2 α 1 -selective: prazosin (Hypotens ) doxazosin (Cardoral, Cadex, Doxaloc ) terazosin (Hytrin )
45 α 1 -blockers - ADEs postural hypotension (1 st -dose syncope) fatigue headache
46 α 1 -blockers - DDIs other hypotensives effect may be decreased by NSAIDs α 1 -blockers - precautions reflex tachycardia upon initiation (short-term β-blocker)
47 α 1 -blockers - therapeutic considerations reflex tachycardia upon initiation (short-term β-blocker) for mild-moderate HTN usually in combination Tx minimal effect on CO, renal function may improve lipid profile may increase mortality risk in HF patients additional benefit in benign prostate hypertrophy (BPH)
48 Therapeutic options: Diuretics β-blockers α 1 -blockers Calcium-channel blockers RAAS modifiers Other
49 CCBs - subclasses Dihydropyridines HTN-Tx nifedipine (Pressolat, (Osmo)Adalat ) amlodipine (Norvasc, Amlow ) lercanidipine (Vasodip ) felodipine (Logimax )
50 CCBs - subclasses Non-dihydropyridines arrhythmia, IHD verapamil (Ikacor /Ikapress, Veracor /Verapress ) (phenylalkylamine - negative inotropic, minimally vasodilating) diltiazem (Dilatam /Dilapress /Adizam ) (benzothiazepine - intermediate inotrpic/vasodilator) relative affinity to nifedipine diltiazem verapamil cardiac Ca ++ channels vascular Ca ++ channels
51 CCBs - mechanism myocardial and smooth muscle cells dihydropyridine CCB administration artery dilation peripheral resistance intracellular calcium blood pressure muscle contraction
52 CCBs - ADEs hypotension constipation fatigue headache peripheral and pulmonary edema
53 CCBs - DDIs nifedipine - with many drugs: - H 2 blockers, omeprazole - antimicrobials (ciprofloxacin, macrolides, azoles) - levodopa - metoprolol - antieplipetic drugs (phenytoin, valproic acid, phenobarbital) - digoxin less with newer dihydropyridines (amlodipine)
54 CCBs - DDIs diltiazem - with many drugs: - amiodarone - β-blockers - azole antifungals, macrolides, ciprofloxacin - metoprolol - statins - digoxin - antieplipetic drugs (phenytoin, valproic acid, phenobarbital) - grapefruit juice
55 CCBs - DDIs verapamil - with many drugs: - amiodarone - β-blockers - azole antifungals, erythromycin - lithium - statins - digoxin - theophylline - grapefruit juice
56 CCBs - therapeutic considerations intrinsic natriuretic effect (no diuretic required) generally safe in asthma, diabetes, IHD may be effective as monotherapy avoid verapamil in CHF additional benefit: certain arrhythmias
57 Therapeutic options: Diuretics β-blockers α 1 -blockers Calcium-channel blockers RAAS modifiers Other
58 RAAS modifiers
59 RAAS modifiers - ACEIs captopril (Aceril ) enalapril (Convertin, Enaladex ) cilazapril (Vascace, Cilaril ) ramipril (Tritace, Ramitens ) lisinopril (Tensopril ) moexipril (Perdix ) benazepril (Cibacen ) 59 fixed combinations with HCTZ
60 RAAS modifiers - ACEIs 60
61 RAAS modifiers - ACEIs angiotensin-converting enzyme angiotensin-i ACEIs other enzymes vasoconstriction angiotensin-ii aldosterone bradykinin 61 water retention sodium retention vasoconstriction
62 RAAS modifiers - ACEIs angiotensin-converting enzyme angiotensin-i ACEIs other enzymes vasoconstriction angiotensin-ii aldosterone bradykinin 62 water retention sodium retention vasoconstriction
63 RAAS modifiers - ACEIs CO increased: bradykinin, aldosterone, epinephrine water and sodium retention BP vascular resistance 63
64 RAAS modifiers - ACEIs PK: adequate oral absorption (empty stomach) most ACEIs are prodrugs (hepatic activation) PK T 1/2-2-12hr; PD - longer for most ACEIs: renal elimination 64
65 RAAS modifiers - ACEIs ADEs: postural hypotn renal impairment angioedema (0.13%) dry cough (20%) bradykinin hyperkalemia 65
66 RAAS modifiers - ACEIs DDIs: potassium-sparing agents, potassium supplements hypoglycemics (improved insulin sensitivity) NSAIDs (vasoconstriction, renal effect) lithium (decreased renal clearance of Li) 66
67 RAAS modifiers - ACEIs additional benefits: HF diabetes post-mi proteinuric chronic renal failure 67
68 RAAS modifiers - ARBs (ATRAs) losartan (Ocsaar, Lotan ) valsartan (Diovan ) candesartan (Atacand ) olmesartan (Olmetec ) fixed combinations with HCTZ 68
69 RAAS modifiers - ARBs (ATRAs) 69
70 RAAS modifiers - ARBs (ATRAs) angiotensin-i angiotensin-converting enzyme other enzymes vasoconstriction angiotensin-ii ARBs aldosterone bradykinin 70 water retention sodium retention vasoconstriction
71 RAAS modifiers - ARBs (ATRAs) advantages over ACEIs: more complete angiotensin-ii blockade no effect on bradykinin 71
72 RAAS modifiers - ARBs (ATRAs) PK: good oral absorption long T 1/2, once-daily administration combined renal-fecal elimination 72
73 RAAS modifiers - ARBs (ATRAs) ADEs: generally similar to those of ACEIs cough ( ) angioedema 73
74 RAAS modifiers - ARBs (ATRAs) DDIs - similar to those of ACEIs: potassium-sparing agents, potassium supplements hypoglycemics (improved insulin sensitivity) NSAIDs (vasoconstriction, renal effect) lithium (decreased renal clearance of Li) 74
75 RAAS modifiers - ARBs (ATRAs) additional benefits similar to those of ACEIs: HF diabetes post-mi proteinuric chronic renal failure 75
76 RAAS modifiers - aldosterone antagonist spironolactone (Aldospirone ) potassium-sparing diuretic not as monotherapy for HTN (excessive fluid retention, reflex tachycardia) hyperkalemia, hyponatremia, gynecomastia might decrease effect of digoxin (hyperkalemia) additional benefit - CHF 76
77 Therapeutic options: Diuretics β-blockers α 1 -blockers Calcium-channel blockers RAAS modifiers Other
78 Centrally-acting adrenergic drugs 1. clonidine (Normopressan ) α 2 -agonist inhibition of adrenergic activity BP devoid of renal effect H 2 O, Na + retention: combine with diuretic sedation, nasal dryness gradual tapering-off (rebound)
79 Centrally-acting adrenergic drugs 2. α-methyl dopa (Aldomin ) methylnorepinephrine prodrug, centrally active inhibition of adrenergic activity TPR, BP CO and organ blood supply unchanged devoid of renal effects sedation, drowsiness, dry mouth, impaired LFTs 1 st choice in pregnancy
80 Direct vasodilators smooth muscle relaxation peripheral resistance BP
81 Direct vasodilators 1. hydralazine most active in arteries, peripheral resistance non-teratogenic ADEs: nausea, sweating, lupus-like syndrome (rare) devoid of renal effect H 2 O, Na + retention: combine with diuretic
82 Direct vasodilators 2. minoxidil mainly active in arteries for Tx of refractory HTN ADEs: severe reflex tachycardia, peripheral edema; hair growth
83 Direct vasodilators β-blocker renin activity smooth muscle relaxation peripheral resistance cardiac activity H 2 O, Na + retention BP BP HR, O 2 demand diuretic
84 JNC-7 guidelines 2003
85 JNC-7 guidelines 2003 Widely accepted 1 st line therapy: low-dose HCTZ change drug? goal unmet? increase dose? add 2 nd drug?
86 JNC-7 guidelines 2003 thiazide-type diuretics should be initial drug therapy for most, either alone or combined with other drug classes. certain high-risk conditions are compelling indications for other drug classes. most patients will require two or more antihypertensive drugs to achieve goal BP. if BP is >20/10 mmhg above goal, initiate therapy with two agents, one usually should be a thiazide-type diuretic.
87 JNC-7 guidelines 2003 Lifestyle Modifications Not at Goal Blood Pressure (<140/90 mmhg) (<130/80 mmhg for those with diabetes or chronic kidney disease) Initial Drug Choices Without Compelling Indications With Compelling Indications Stage 1 HTN: (SBP or DBP mmhg): Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination. Stage 2 HTN (SBP >160 or DBP >100 mmhg): 2-drug combination for most (usually thiazide + ACEI/ARB/BB/CCB) Not at Goal Blood Pressure Bi-functional drugs: (diuretics, ACEI, ARB, BB, CCB) as needed. Optimize dosages or add additional drugs until goal blood pressure is achieved. Consider consultation with HTN specialist.
88 JNC-7 guidelines 2003
89 JNC-7 guidelines 2003 Potential favorable effects of HTN-Tx: thiazide-type diuretics useful in slowing demineralization in osteoporosis. BBs useful in the treatment of atrial tachyarrhythmias/fibrillation, migraine, thyrotoxicosis (short-term), essential tremor, or perioperative HTN. CCBs useful in Raynaud s syndrome and certain arrhythmias. α-blockers useful in prostatism.
90 JNC-7 guidelines 2003 Potential unfavorable effects of HTN-Tx: thiazide diuretics should be used cautiously in gout or a history of significant hyponatremia. BBs should be generally avoided in patients with asthma, reactive airways disease, or second- or third-degree heart block. ACEIs and ARBs: C/I in pregnancy ACEIs should not be used with a history of angioedema. aldosterone antagonists and K + -sparing diuretics can cause hyperkalemia.
91 JNC-7 guidelines 2003 (non)adherence issues JNC-8 expected release: 2011
92
93 Current trends Outcomes dependent on achieved BP reduction regardless of therapeutic class beta-blockers less preferred, unless additional indication newer CCBs and RAAS modifiers appealing due to effectiveness, convenience and safety
94 Discontinuation of antihypertensive Tx When to D/C? well-controlled, mild HTN lifestyle modifications importance of patient characteristics
95 Discontinuation of antihypertensive Tx How to D/C? gradual withdrawal preferred abrupt cessation of short-acting β-blockers (propranolol) and α 2 -agonists (clonidine) might cause a fatal withdrawal syndrome these should therefore be tapered-off over weeks
96 - hypertension DRUGS FOR EXAM hydrochlorothiazide spironolactone propranolol metoprolol doxazosin amlodipine diltiazem verapamil enalapril losartan clonidine hydralazine α-methyl-dopa 96
7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationHeart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid
Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension
More informationSection 3, Lecture 2
59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationHYPERTENSION: Sustained elevation of arterial blood pressure above normal o Systolic 140 mm Hg and/or o Diastolic 90 mm Hg
Lecture 39 Anti-Hypertensives B-Rod BLOOD PRESSURE: Systolic / Diastolic NORMAL: 120/80 Systolic = measure of pressure as heart is beating Diastolic = measure of pressure while heart is at rest between
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationAntihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment
Approaches to Hypertension Treatment Antihypertensives Inhibit Sympathetic impulses Inhibit contractility Inhibit heart rate Inhibit vasoconstriction Inhibit smooth muscle function Inhibit RAAS Inhibit
More informationHypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
More informationsympatholytics sympatholytics sympatholytics
sympatholytics sympatholytics sympatholytics CNS-ACTING SYMPATHOPLEGICS Sympathetic brain signals Doesn t affect baroreceptor reflex (no orthostatic hypotension) Methyldopa α-methylne crosses BBB (+) α-adrenoreceptors
More informationChapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
More informationIntroduction. Factors affecting blood pressure: 1-COP = HR X SV mainly affect SBP. 2-TPR = diameter of arterioles X viscosity of blood affect DBP
Introduction Hypertension is a persistent elevation of blood pressure above 140 / 90 mmhg for more than three sitting. (0ptimal level
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More informationTowards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:
Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood: Cardiac Output (CO) CO=SVxHR (stroke volume x heart rate) Cardiac output: The amount of blood
More informationWhat in the World is Functional Medicine?
What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationHypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC
HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided
More informationAntihypertensives. Diagnostic category
Measurement of blood pressure At first assessment, take both arms then choose the one with the higher reading. Beware of orthostatic hypotension. Measure BP in sitting position, and repeat after patient
More informationChapter 10 Worksheet Blood Pressure and Antithrombotic Agents
Complete the following. 1. A layer of cells lines each vessel in the vascular system. This layer is a passive barrier that keeps cells and proteins from going into tissues; it also contains substances
More informationHypertension. Penny Mosley MRPharmS
Hypertension Penny Mosley MRPharmS Outline of presentation Introduction to hypertension Physiological control of arterial blood pressure What determines our bp? What determines the heart rate? What determines
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationHypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati
CHAPTER-I CARDIOVASCULAR SYSTEM Hypertension SUB: PHARMACOTHERAPEUTICS-I CODE:T0820006 Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati Hypertension
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationByvalson. (nebivolol, valsartan) New Product Slideshow
Byvalson (nebivolol, valsartan) New Product Slideshow Introduction Brand name: Byvalson Generic name: Nebivolol, valsartan Pharmacological class: Beta-blocker + angiotensin II receptor blocker (ARB) Strength
More informationBeta 1 Beta blockers A - Propranolol,
Pharma Lecture 3 Beta blockers that we are most interested in are the ones that target Beta 1 receptors. Beta blockers A - Propranolol, it s a non-selective competitive antagonist of beta 1 and beta 2
More information1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias
1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias Only need to know drugs discussed in class At the end of this section you should
More informationAntihypertensive drugs: I. Thiazide and other diuretics:
Clinical assessment of hypertensive patient: You have to take history regarding the presence of other risk factors for CAb like diabetes mellitus, smoking, etc. Take history whether the patient takes medications
More informationAntihypertensive Agents
Antihypertensive Agents Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 7, 08, presented by Ezra Levy, Pharm.D! Usual Dose,
More informationHypertension Management - Summary
Who should have blood pressure assessed? Hypertension Management - Summary All patients over the age of 40 years, every 1-3 years in order to determine their cardiovascular risk (ie. Framingham Risk Score)
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationTreatment of Essential Hypertension
2016 edition by Mark A. Simmons, PhD Department of Pharmaceutical Sciences School of Pharmacy University of Maryland Eastern Shore Originally developed by Hugh J. Burford, PhD, FCP Department of Pharmacology
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationHYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP
HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP What is normal blood pressure? Prehypertension 130-139/80-90 Compared with normal BP Double the risk for developing hypertension. Lifestyle
More information8/20/2018. Objectives. What is hypertension? cont. What is hypertension? Epidemiology cont. Epidemiology
Objectives Hypertension (high blood pressure): Clinical Pearls for the Pharmacy Technician Tanya Schmidt PharmD, RPh Director of Central Operations at Thrifty White Pharmacy North Dakota Board of Pharmacy
More informationTreatment of Essential Hypertension
2016 edition by Mark A. Simmons, PhD Department of Pharmaceutical Sciences School of Pharmacy University of Maryland Eastern Shore Originally developed by Hugh J. Burford, PhD, FCP Department of Pharmacology
More informationAntihypertensive Agents
Antihypertensive Agents Öner Süzer www.onersuzer.com osuzer@istanbul.edu.tr Last update: 13.11.2009 1 Süzer Farmakoloji 3. Baskı 2005 2 1 Süzer Farmakoloji 3. Baskı 2005 3 Süzer Farmakoloji 3. Baskı 2005
More informationPharmacologic Management of Hypertension
Current Concepts In Management of Fernando Vega, MD Secondary - Definition Renovascular Disease (The kidney doesn t get impressed by blood pressure) Renovascular stenosis Renal artery stenosis Fibromuscular
More informationDr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None
Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationCategories of HTN. Overview of Hypertension. Types of Hypertension
Categories of HTN Overview of Hypertension Normal SBP 100 Quick review of the Basics: What is
More informationUniversity of Al Qadisiyah College of Pharmacy Dr. Bassim I Mohammad, MBChB, MSc, Ph.D
University of Al Qadisiyah College of Pharmacy Dr. Bassim I Mohammad, MBChB, MSc, Ph.D Cardiovascular Pharmacology 1. Antihypertensives 2. Antianginal 3. Drugs for HF 4. Antiarrythemics 5. Drugs for Hyperlipoproteniemia
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationTREATMENT OF HYPERTENSION
TREATMENT OF HYPERTENSION Aim of treatment BP Goals Main items of treatment Lifestyle modification When to start drug Rx Pharmacological therapy 1. Relief of symptoms 2. Prevention of complications and
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationLESSON ASSIGNMENT. After completing this lesson you will be able to:
LESSON ASSIGNMENT SUBCOURSE MD0806 LESSON 7 Therapeutics III. Antihypertensive Agents. LESSON ASSIGNMENT Paragraphs 7-1--7-12. LESSON OBJECTIVES After completing this lesson you will be able to: 7-1. From
More informationDRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI
DRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI 3. Vasodilators Drugs which dilate blood vessels ( decrease peripheral vascular resistance) by acting on smooth muscle cells through non-autonomic mechanisms:
More informationANTI- HYPERTENSIVE AGENTS
CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is
More informationDRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)
DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationCombining Antihypertensives in People with Diabetes
Combining ntihypertensives in People with Diabetes The majority of people with diabetes will develop hypertension and this subsequently increases the risk of microvascular and macrovascular complications.
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationTop 200 Section 4. Cardiovascular Drugs
Top 200 Section 4 Cardiovascular Drugs Objectives After finishing this presentation the audience should be able to: Describe conditions/disease states that would make a person a candidate for drug therapy.
More informationANTIHYPERTENSIVES. Assoc. Prof. Bilgen Başgut
ANTIHYPERTENSIVES Assoc. Prof. Bilgen Başgut Hypertension Hypertension is a condition in which the blood pressure is persistently higher than normal Hypertension > 140 mmhg > 90 mmhg Systolic Blood Pressure
More informationChapter (9) Calcium Antagonists
Chapter (9) Calcium Antagonists (CALCIUM CHANNEL BLOCKERS) Classification Mechanism of Anti-ischemic Actions Indications Drug Interaction with Verapamil Contraindications Adverse Effects Treatment of Drug
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationHypertension and the Challenge of Adherence. Geneva Clark Briggs, Pharm.D., BCPS
Hypertension and the Challenge of Adherence Geneva Clark Briggs, Pharm.D., BCPS Outline Brief overview of HTN and pharmacologic therapies Role of pharmacists in collaboration with patients and physicians
More informationManagement of Hypertension. Ahmed El Hawary MD Suez Canal University
Management of Hypertension Ahmed El Hawary MD Suez Canal University Minimal vs. Optimal Care Resources more than science affect type of care and level of management. what is possible (minimal care) and
More informationM2 TEACHING UNDERSTANDING PHARMACOLOGY
M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014 TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationNetwork Hypertension Algorithm
Network Hypertension Algorithm Content Review and Approval: This document is subject to review, revision, and (re)approval by the Clinical Integration and Oversight Committee (CIOC) annually and following
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationHeart Failure. Dr. Alia Shatanawi
Heart Failure Dr. Alia Shatanawi Left systolic dysfunction secondary to coronary artery disease is the most common cause, account to 70% of all cases. Heart Failure Heart is unable to pump sufficient blood
More informationLab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide
Lab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide Main Idea: The function of the circulatory system is to maintain adequate blood flow to all tissues. Clinical
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More information4/3/2018 PHARMACOLOGICAL MANAGEMENT OF HYPERTENSION IN THE PATIENT WITH CKD TONI A. HARPS, APRN-CNS, MSN NEPHROLOGY WHY THIS TOPIC/OBJECTIVES
PHARMACOLOGICAL MANAGEMENT OF HYPERTENSION IN THE PATIENT WITH CKD TONI A. HARPS, APRN-CNS, MSN NEPHROLOGY WHY THIS TOPIC/OBJECTIVES To identify Blood pressure (BP) medications which are used to manage
More information2014 HYPERTENSION GUIDELINES
2014 HYPERTENSION GUIDELINES Eileen M. Twomey, Pharm.D., BCPS 1 Learning Objectives Describe specific blood pressure thresholds at which antihypertensive therapy should be initiated and blood pressure
More informationAntihypertensive Drugs. Nafrialdi
Antihypertensive Drugs Nafrialdi 1 Mechanisms of Blood Pressure Regulation Blood Presure Cardiac Output Peripheral Resistance Heart Rate Stroke volume Vascular tone Vessel elasticity Myocardial contractility
More informationProf dr Aleksandar Raskovic DIRECT VASODILATORS
Prof dr Aleksandar Raskovic DIRECT VASODILATORS Direct vasodilators Minoxidil (one of the most powerful peripheral arterial dilators) Opening of KATP channels, efflux of K, lose of Ca and smooth muscle
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationHypertension: Update
Hypertension: Update Meenakshi A Bhalla MD,FACC Associate Professor of Medicine Director Preventive Cardiology Advanced Heart Failure and Transplant Cardiology University of Kentucky Faculty Disclosure
More informationCardiovascular Clinical Practice Guideline Pilot Implementation
Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high
More informationCardiovascular Pharmacotherapy
Cardiovascular Pharmacotherapy Overview Mechanism of cardiovascular drugs Indications and clinical use in cardiology Renin-Angiotensin Inhibitors: Angiotensin-Converting Enzyme Inhibitors, Angiotensin
More informationCirculation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.
Circulation Blood Pressure and Antihypertensive Medications Two systems Pulmonary (low pressure) Systemic (high pressure) Aorta 120 mmhg Large arteries 110 mmhg Arterioles 40 mmhg Arteriolar capillaries
More informationLayered Approaches to Studying Drug Responses
Layered Approaches to Studying Drug Responses Brian B Hoffman, MD Chief of Medicine VA Boston Health Care System Professor of Medicine Harvard Medical School Conflict of Interest: US Federal Grant Funding
More informationPharmacology of the Sympathetic Nervous System II
Pharmacology of the Sympathetic Nervous System II Edward JN Ishac, Ph.D. Professor Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More informationAngina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris.
Lonet Tablet Description Lonet contains Atenolol, a synthetic β1 selective (cardioselective) adrenoreceptor blocking agent without membrane stabilising or intrinsic sympathomimetic (partial agonist) activity.
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationExplore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management
Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management Jeong Bae Park, MD,PhD Dept of Med/Cardiology, Cheil General Hospital, Kwandong University College of Medicine Apr
More informationNew classification of HT Systolic Diastolic Normal <120 <80 Prehypertension Stage1HT Stage 2 HT >160 or >100
Hypertension 1 Definition Hypertension can be defined as a condition where blood pressure is elevated to an extent that clinical benefit is obtained from blood pressure lowering. it is an important risk
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More information